Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 15/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2799687 | 0.94 | STAT6 (0.40) | SMN1; SMN2THRBSTAT6ENPP2 | |
| SCHEMBL2802391 | 0.93 | SMN1; SMN2 (0.41) | SMN1; SMN2TP53THRBSTAT6ENPP2 | |
| SCHEMBL2802693 | 0.92 | TP53 (0.41) | CCR1SMN1; SMN2TP53CHRM4STAT6 | |
| SCHEMBL2801433 | 0.92 | TP53 (0.39) | TP53THRB | |
| SCHEMBL2798553 | 0.91 | THRB (0.37) | SMN1; SMN2TP53THRBSTAT6ENPP2 | |
| SCHEMBL2801054 | 0.90 | CCR1 (0.45) | CCR1SMN1; SMN2TP53THRBCHRM4 | |
| SCHEMBL2802186 | 0.89 | VNN1 (0.43) | — | |
| SCHEMBL2804072 | 0.88 | STAT6 (0.41) | SMN1; SMN2THRBSTAT6ENPP2 | |
| SCHEMBL2802824 | 0.88 | STAT6 (0.39) | SMN1; SMN2THRBSTAT6ENPP2 | |
| SCHEMBL2803544 | 0.88 | TPSAB1 (0.40) | SMN1; SMN2TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206714-B1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8729264-B2 | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2206714-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | TYR, CUTA, SERPINB1 | CCR1 3583/4885SMN1; SMN2 2769/4885TP53 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.